Izotropic's IzoView Is Weeks Away From Final Engineering & Showcasing to Investment and Scientific Communities
Izotropic's IzoView Is Weeks Away From Final Engineering & Showcasing to Investment and Scientific Communities
Vancouver, British Columbia--(Newsfile Corp. - October 25, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces that the engineering and construction of IzoView is weeks away from completion and subsequent unveiling to existing shareholders, and the investment, medical and scientific communities.
温哥华,不列颠哥伦比亚省-(Newsfile Corp.-2022年10月25日)-Izotrotic公司(CSE:以藏)(OTCQB:IZOZF)(FSE:1R3) ("各向同性“或”公司IzoView是一家将IzoView商业化的医疗设备公司,IzoView是一种专用的乳房CT(计算机断层扫描)成像平台,用于更准确地检测和诊断乳腺癌。该公司宣布,IzoView的设计和建造将在几周后完成,并随后向现有股东、投资、医疗和科学界揭开面纱。
Full assembly of IzoView is approximately four weeks from completion, and the imaging subsystem is currently operational and producing static images with phantoms. Phantoms are stand-in objects for human tissue that are used to confirm the device is operating correctly. The final assembly of IzoView will be completed upon receipt of exterior parts that comprise the tabletop, footbox, and headbox, including the housing for the attached computer workstation.
IzoView的全部组装大约需要4周时间才能完成,成像子系统目前正在运行,并产生带有幻影的静态图像。模体是人体组织的替代对象,用于确认设备运行正常。IzoView的最终组装将在收到组成桌面、脚箱和流浆箱的外部部件后完成,包括所连接的计算机工作站的外壳。
Investors can expect news releases on the following milestones and corporate catalysts through to the end of 2022:
投资者可以期待在2022年底之前发布关于以下里程碑和企业催化剂的新闻:
- Announcement of IzoView's full-motion, 360-degree 3D image capture of phantom images.
- Unveiling of IzoView with photographs and video.
- Further advancements of machine learning image reconstruction algorithms in partnership with Johns Hopkins University School of Medicine.
- Milestone plans with projected timelines through the clinical study to the sale of the first IzoView device.
- Overview of pricing and financial models.
- New corporate materials, social media, and marketing plans.
- IzoView宣布推出360度全动态3D影像捕捉功能。
- 带照片和视频的IzoView揭幕。
- 与约翰·霍普金斯大学医学院合作的机器学习图像重建算法的进一步进展.
- 从临床研究到销售第一台IzoView设备的里程碑式计划,以及预计的时间表。
- 定价和财务模型概述。
- 新的企业材料、社交媒体和营销计划。
"I want to thank shareholders for being exceedingly patient with the various delays and my conservative nature in respect to disclosure. With the development stage coming to completion, filing of important IP and the forthcoming presentation of our device, the Company will be communicating with greater frequency as we move to the next stage," said Dr. John McGraw, CEO.
首席执行官约翰·麦格劳博士说:“我要感谢股东们对各种延迟和我在信息披露方面的保守态度表现出了极大的耐心。随着开发阶段接近完成、重要知识产权的申请以及我们即将推出的设备,随着我们进入下一阶段,公司将以更频繁的方式进行沟通。”
The History of IzoView Breast CT:
IzoView乳腺CT的历史:
Four successive breast CT imaging systems have been built at UC Davis Medical Centre in California by Company Director and Principal Founder of breast CT, Dr. John M. Boone. Each of these systems had better clinical utility and image performance than its predecessor. The latest system has incorporated lessons learned from previous models, and the incorporation of state-of-the-art subcomponents have improved clinical utility with exceptional high-resolution CT images of the breast. Izotropic holds the rights to this breast CT technology under its exclusive global License Agreement with The Regents of the University of California.
由董事公司和乳腺CT的主要创始人约翰·M·布恩博士在加州大学戴维斯医学中心建造了四个连续的乳腺CT成像系统。这些系统中的每一个都比它的前身具有更好的临床实用性和成像性能。最新的系统吸收了从以前模型中吸取的经验教训,并结合了最先进的子组件,通过出色的高分辨率乳房CT图像提高了临床实用性。根据与加州大学董事会签订的独家全球许可协议,Izotroy公司拥有这项乳房CT技术的权利。
The Company's original strategy was to closely mirror the 4th generation Breast CT device that has been under clinical investigation and clinical trials at UC Davis Medical Center and imaged close to 600 patients to date. The intention was for the Company to mirror the 4th generation breast CT unit with minor upgrades for its FDA study and finalize user and patient handling requirements afterwards. As Covid-19 set in, the Company began to factor the evolving dynamics, the impacts on supply chains, and the associated challenges of running a clinical study during a pandemic. At the same time, next-generation primary components became available, and the Company, therefore, decided to adjust the business plan to its benefit. As a result, now going into the initial clinical study, comparing IzoView with diagnostic mammography, Izotropic expects to deliver a better-performing system and have a subsequent broader product offering and a more competitively priced Breast CT system.
该公司最初的战略是与加州大学戴维斯分校医学中心一直在进行临床研究和临床试验的第四代乳房CT设备密切相关,迄今已为近600名患者成像。其目的是为了让公司反映出4这是为FDA的研究和最终确定用户和患者的处理要求,为FDA研究和最终确定用户和患者处理要求的新一代乳房CT设备。随着新冠肺炎的启动,该公司开始考虑不断变化的动态、对供应链的影响以及在大流行期间开展临床研究的相关挑战。与此同时,下一代主要组件已面市,因此,公司决定调整业务计划,使其受益。因此,现在进入最初的临床研究,将IzoView与诊断性乳房X光照相进行比较,Izotroy预计将提供性能更好的系统,并随后提供更广泛的产品和更具竞争力的乳腺CT系统。
More than U.S. $25M has been invested across all aspects of the breast CT system, with the majority of this capital on R&D and clinical studies at UC Davis Medical Center, funded primarily by the National Institutes of Health in the U.S. Over the past 2 years Izotropic has made specific investments related to engineering capabilities, onboarding personnel, and investigating and finalizing the IzoView platform strategy. The Company has also advanced its technical planning and documentation, sourced, and purchased critical components, established redundant manufacturing sources, and implemented a quality management system, which is all necessary to make IzoView a high-performing device for mass use.
在乳腺CT系统的各个方面已经投资了超过2500万美元,其中大部分资金用于加州大学戴维斯分校医疗中心的研发和临床研究,资金主要由美国国立卫生研究院提供。在过去的两年里,Izotroy在工程能力、入职人员以及调查和最终确定IzoView平台战略方面进行了具体投资。该公司还推进了技术规划和文件编制,采购和购买了关键部件,建立了冗余的制造来源,并实施了质量管理体系,这些都是使IzoView成为大规模使用的高性能设备所必需的。
ON BEHALF OF THE BOARD
Dr. John McGraw
我代表董事会
约翰·麦格劳博士
Investor Relations Contact:
James Berard
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
投资者关系联系人:
詹姆斯·贝拉德
电子邮件:info@izocorp.com
免费电话:1-833-IZOCORP分机1
Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
媒体问询联系人:
雅克林·塔斯特
电子邮件:Jaclyn@izocorp.com
免费电话:1-833-IZOCORP转3
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
关于Izotroy公司
Izotroy公司是唯一一家将专门的乳腺CT成像平台IzoView商业化的上市公司,该平台用于更准确地检测和诊断乳腺癌。为了加快患者和供应商使用IzoView的速度,Izotroy的初步临床研究打算证明诊断性乳房CT成像比诊断性乳房X光检查程序具有更好的性能。在后续的临床研究中,Izotroy公司打算验证平台应用,包括放射学中的乳房筛查、外科肿瘤学中的治疗计划和监测,以及整形和重建外科中的乳房重建和植入监测。
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
欲了解有关Izotroy公司的更多信息,请访问公司网站:izocorp.com,或查看公司在SEDAR上的简介:sedar.com。
Forward-Looking Statements
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible,
前瞻性陈述
本文档可能包含“前瞻性陈述”,这些陈述基于对公司管理层、业务的当前估计、假设、预测和预期,以及对公司运营所处的相关市场和经济环境的了解。在可能的情况下,公司已尝试
to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of
通过使用诸如“预期”、“相信”、“设想”、“估计”、“预期”、“打算”、“可能”、“计划”、“预测”、“项目”、“目标”、“潜在”、“将会”、“可能”、“应该”、“继续”、“考虑”和其他类似的表达及其派生的词语来识别此类信息和陈述
future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
未来事件、趋势或前景,或未来的经营或财务业绩,尽管并非所有前瞻性陈述都包含这些识别词汇。
These statements are not guarantees of performance and involve risks including those related to capital requirements, and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.
这些陈述不是对业绩的保证,涉及风险,包括与资本要求有关的风险,以及难以控制或预测的不确定性,因此,它们可能导致公司未来活动的结果与此类陈述的内容和影响大不相同。前瞻性陈述仅在作出之日起具有相关性,公司没有义务更新或修改任何前瞻性陈述,以反映新的信息或未来事件或情况的发生,除非法律另有要求。本公司及其股东、高级管理人员和顾问均不对任何人根据本文所含信息采取的任何行动以及任何行动的结果负责,包括但不限于购买或出售公司证券。本文档中的任何内容都不应被视为任何类型的医疗或其他建议。所有图片仅用于说明目的。IzoView尚未获准出售。
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问